Damora Therapeutics, Inc.
DMRA
Jodie situation report
Damora Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.
- DMRA's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if DMRA's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind DMRA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
INCYIncyte CorporationcompetitorMar 19, 2026 ▾
“The expected combination of increased clinical activity and longer half-life is predicted to enable the delivery of sufficient amounts of DMR-001 via subcutaneous injection to match and potentially exceed the reported efficacy of INCA033989 that was intraveno…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 6 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
DMRA is currently a Early Follower in the organic co-movement group Marine Shipping & Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for DMRA; it is not active in the latest market snapshot.